Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

New Delhi: Biotechnology major Biocon on Monday said its wholly-owned subsidiary Biocon Biologics has received a positive recommendation from the European Medicines Agency's panel for its breast cancer biosimilar Pertuzumab.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation to the Pertuzumab biosimilar (420 mg concentrate solution for infusion) under the brand name Pebrilzo, the company said in a statement.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.